PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1
- 1 February 2007
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 292 (2) , E421-E434
- https://doi.org/10.1152/ajpendo.00157.2006
Abstract
High-fructose consumption is associated with insulin resistance and diabetic dyslipidemia, but the underlying mechanism is unclear. We show in hamsters that high-fructose feeding stimulated forkhead box O1 (FoxO1) production and promoted its nuclear redistribution in liver, correlating with augmented apolipoprotein C-III (apoC-III) production and impaired triglyceride metabolism. High-fructose feeding upregulated peroxisome proliferator-activated receptor-γ coactivator-1β and sterol regulatory element binding protein-1c expression, accounting for increased fat infiltration in liver. High-fructose-fed hamsters developed hypertriglyceridemia, accompanied by hyperinsulinemia and glucose intolerance. These metabolic aberrations were reversible by fenofibrate, a commonly used anti-hypertriglyceridemia agent that is known to bind and activate peroxisome proliferator-activated receptor-α (PPARα). PPARα physically interacted with, but functionally antagonized, FoxO1 in hepatic apoC-III expression. These data underscore the importance of FoxO1 deregulation in the pathogenesis of hypertriglyceridemia in high-fructose-fed hamsters. Counterregulation of hepatic FoxO1 activity by PPARα constitutes an important mechanism by which fibrates act to curb apoC-III overproduction and ameliorate hypertriglyceridemia.Keywords
This publication has 55 references indexed in Scilit:
- Aberrant Forkhead Box O1 Function Is Associated with Impaired Hepatic MetabolismEndocrinology, 2006
- Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolismJournal of Clinical Investigation, 2006
- Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemiaAtherosclerosis, 2006
- Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver DiseaseJournal of Biological Chemistry, 2004
- Mechanisms of metabolic dyslipidemia in insulin resistant states deregulation of hepatic and intestinal lipoprotein secretionFrontiers in Bioscience-Landmark, 2003
- Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed HamsterPublished by Elsevier ,2002
- The Mechanisms of Action of PPARsAnnual Review of Medicine, 2002
- Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal ObesityArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- DNA Binding Preferences of PPARα/RXRα HeterodimersBiochemical and Biophysical Research Communications, 1997
- Effect of serum and C‐apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipaseFEBS Letters, 1976